The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IFRX | -5.81% | -61.78% | -17.48% | -90% |
| S&P | +19.89% | +109.18% | +15.89% | +164% |
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.
A key EUA from the FDA for the company's COVID-19 therapy gave the stock a jolt.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.04M | 553.6% |
| Gross Profit | -$2.68M | -627.6% |
| Gross Margin | -5985.37% | -608.7% |
| Market Cap | $53.04M | -48.2% |
| Market Cap / Employee | $0.80M | 0.0% |
| Employees | 66 | 0.0% |
| Net Income | -$16.35M | -9.7% |
| EBITDA | -$15.59M | 5.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $15.26M | -25.6% |
| Accounts Receivable | $0.10M | 0.0% |
| Inventory | 5.9 | -42.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.24M | -62.9% |
| Short Term Debt | $0.46M | 8.9% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -54.58% | 0.0% |
| Return On Invested Capital | -47.18% | -5.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.73M | 24.8% |
| Operating Free Cash Flow | -$9.72M | 24.9% |
| Metric | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.00 | 1.02 | 0.82 | 0.70 | -12.13% |
| Price to Sales | 1399.08 | 841.85 | 894.36 | 488.47 | - |
| Price to Tangible Book Value | 1.00 | 1.02 | 0.82 | 0.70 | -12.13% |
| Enterprise Value to EBITDA | -1.41 | -1.57 | 0.41 | 0.14 | -246.91% |
| Return on Equity | -44.4% | -47.6% | -45.2% | -62.4% | - |
| Total Debt | $1.07M | $1.00M | $0.76M | $0.70M | -41.08% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
